Akari Therapeutics Stock (NASDAQ:AKTX)

Forecast Revenue Ownership Financials Chart

Previous Close

$0.27

52W Range

$0.22 - $1.73

50D Avg

$0.35

200D Avg

$0.88

Market Cap

$4.86K

Avg Vol (3M)

$1.16M

Beta

0.28

Div Yield

AKTX Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

Employees

IPO Date

Jan 06, 2014

Website

AKTX Performance

AKTX Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-21.64M	$-16.81M	$-23.09M
Net Income	$-19.79M	$-10.01M	$-6.97M
EBITDA	$-21.64M	$-16.80M	$-23.08M
Basic EPS	-	-	-
Diluted EPS	-	-	-

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q4 17Mar 21, 18 | 8:30 AM

Peer Comparison

Ticker	Company
PPBT	Purple Biotech Ltd.
XAGE	Longevity Health Holdings Inc.
MSPR	MSP Recovery, Inc.
PBM	Psyence Biomedical Ltd.
SYRS	Syros Pharmaceuticals, Inc.
VRPX	Virpax Pharmaceuticals, Inc.
CDT	CDT Equity Inc.
VINC	Vincerx Pharma, Inc.
DRMA	Dermata Therapeutics, Inc.
REVB	Revelation Biosciences, Inc.